山东华铂凯盛生物科技

Huabo Kaisheng (Shandong) Bio-tech Co., Ltd. is a pharmaceutical research and development enterprise headquartered in Jinan, China. Founded in 2016, the company specializes in the discovery and development of innovative small molecule drugs (Class 1), improved new drugs (Class 2), and high-end generic formulations. Its primary therapeutic focus areas include oncology, cardiovascular diseases, and metabolic disorders, with a pipeline led by candidates such as HBKS-001 for lung cancer. In addition to its internal drug development programs, Huabo Kaisheng operates as a CRO, providing comprehensive services in medicinal chemistry, formulation research, and clinical registration. The company maintains state-of-the-art R&D facilities designed to meet international quality standards for global drug registration.